Literature DB >> 19793909

Quantitative analysis of Epstein-Barr virus (EBV)-related gene expression in patients with chronic active EBV infection.

Seiko Iwata1, Kaoru Wada, Satomi Tobita, Kensei Gotoh, Yoshinori Ito, Ayako Demachi-Okamura, Norio Shimizu, Yukihiro Nishiyama, Hiroshi Kimura.   

Abstract

Chronic active Epstein-Barr virus (CAEBV) infection is a systemic Epstein-Barr virus (EBV)-positive lymphoproliferative disorder characterized by persistent or recurrent infectious mononucleosis-like symptoms in patients with no known immunodeficiency. The detailed pathogenesis of the disease is unknown and no standard treatment regimen has been developed. EBV gene expression was analysed in peripheral blood samples collected from 24 patients with CAEBV infection. The expression levels of six latent and two lytic EBV genes were quantified by real-time RT-PCR. EBV-encoded small RNA 1 and BamHI-A rightward transcripts were abundantly detected in all patients, and latent membrane protein (LMP) 2 was observed in most patients. EBV nuclear antigen (EBNA) 1 and LMP1 were detected less frequently and were expressed at lower levels. EBNA2 and the two lytic genes were not detected in any of the patients. The pattern of latent gene expression was determined to be latency type II. EBNA1 was detected more frequently and at higher levels in the clinically active patients. Quantifying EBV gene expression is useful in clarifying the pathogenesis of CAEBV infection and may provide information regarding a patient's disease prognosis, as well as possible therapeutic interventions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19793909     DOI: 10.1099/vir.0.013482-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  Relationship of survivin to clinical drug resistance in Burkitt's lymphoma of the head and neck region.

Authors:  Manal M Zyada
Journal:  Med Oncol       Date:  2010-06-04       Impact factor: 3.064

2.  A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Authors:  Christopher P Fox; Tracey A Haigh; Graham S Taylor; Heather M Long; Steven P Lee; Claire Shannon-Lowe; Simon O'Connor; Catherine M Bollard; Javeed Iqbal; Wing C Chan; Alan B Rickinson; Andrew I Bell; Martin Rowe
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

3.  Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States.

Authors:  Jeffrey I Cohen; Elaine S Jaffe; Janet K Dale; Stefania Pittaluga; Helen E Heslop; Cliona M Rooney; Stephen Gottschalk; Catherine M Bollard; V Koneti Rao; Adriana Marques; Peter D Burbelo; Siu-Ping Turk; Rachael Fulton; Alan S Wayne; Richard F Little; Mitchell S Cairo; Nader K El-Mallawany; Daniel Fowler; Claude Sportes; Michael R Bishop; Wyndham Wilson; Stephen E Straus
Journal:  Blood       Date:  2011-03-31       Impact factor: 22.113

4.  Replication of Epstein-Barr virus primary infection in human tonsil tissue explants.

Authors:  Kensei Gotoh; Yoshinori Ito; Seiji Maruo; Kenzo Takada; Terukazu Mizuno; Masaaki Teranishi; Seiichi Nakata; Tsutomu Nakashima; Seiko Iwata; Fumi Goshima; Shigeo Nakamura; Hiroshi Kimura
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

5.  Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferations.

Authors:  Christopher P Fox; Claire Shannon-Lowe; Martin Rowe
Journal:  Herpesviridae       Date:  2011-09-07

6.  Visual detection and evaluation of latent and lytic gene expression during Epstein-Barr virus infection using one-step reverse transcription loop-mediated isothermal amplification.

Authors:  Xiaoying Liu; Jingfeng Tang; Man Wang; Qiang Ma; Yefu Wang
Journal:  Int J Mol Sci       Date:  2013-12-09       Impact factor: 5.923

7.  Role of latent membrane protein 1 in chronic active Epstein-Barr virus infection-derived T/NK-cell proliferation.

Authors:  Takuto Ito; Hidetaka Kawazu; Takayuki Murata; Seiko Iwata; Saki Arakawa; Yoshitaka Sato; Kiyotaka Kuzushima; Fumi Goshima; Hiroshi Kimura
Journal:  Cancer Med       Date:  2014-05-03       Impact factor: 4.452

8.  Anti-tumor effects of suberoylanilide hydroxamic acid on Epstein-Barr virus-associated T cell and natural killer cell lymphoma.

Authors:  Mohammed N A Siddiquey; Hikaru Nakagawa; Seiko Iwata; Tetsuhiro Kanazawa; Michio Suzuki; Ken-Ichi Imadome; Shigeyoshi Fujiwara; Fumi Goshima; Takayuki Murata; Hiroshi Kimura
Journal:  Cancer Sci       Date:  2014-05-13       Impact factor: 6.716

Review 9.  Virus-Driven Carcinogenesis.

Authors:  Yuichiro Hatano; Takayasu Ideta; Akihiro Hirata; Kayoko Hatano; Hiroyuki Tomita; Hideshi Okada; Masahito Shimizu; Takuji Tanaka; Akira Hara
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

10.  The heat shock protein 90 inhibitor BIIB021 suppresses the growth of T and natural killer cell lymphomas.

Authors:  Michio Suzuki; Tadashi Takeda; Hikaru Nakagawa; Seiko Iwata; Takahiro Watanabe; Mohammed N A Siddiquey; Fumi Goshima; Takayuki Murata; Jun-Ichi Kawada; Yoshinori Ito; Seiji Kojima; Hiroshi Kimura
Journal:  Front Microbiol       Date:  2015-04-09       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.